Wells Fargo lowered the firm’s price target on Arvinas (ARVN) to $19 from $26 and keeps an Overweight rating on the shares. The firm thinks Pfizer’s (PFE) decision to remove planned 1L/2L vepdeg combo studies likely speaks to vepdeg’s non-differentiated profile in VERITAC-2. While shares are low on this news, shares trade at about 50% of cash, and Wells thinks there is value in 2L+ for vepdeg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target lowered to $14 from $24 at Piper Sandler
- Arvinas Holding Company: Buy Rating Affirmed Amidst Promising Vepdeg Potential and Strong Financial Position
- Arvinas downgraded to Hold from Buy at TD Cowen
- Arvinas price target lowered to $16 from $32 at Barclays
- Arvinas Reports Strong Q1 2025 Results and Strategic Shift